News

Innovative Collaborations Transform NGS Library Prep Automation

Innovative Collaborations Transform NGS Library Prep Automation

Transforming NGS Library Preparation Through Automation

New England Biolabs (NEB) has made significant strides in enhancing next-generation sequencing (NGS) library preparation by partnering with top automation providers. As the company prepares to showcase their innovations, they highlight collaborative efforts aimed at streamlining workflows for improved efficiency.

Strategic Collaborations with Industry Leaders

Recently, NEB has joined forces with several key players in laboratory automation, including Beckman Coulter Genomics, Eppendorf, Hamilton Company, Revvity, and SPT Labtech. These partnerships allow NEB to leverage specialized knowledge in creating automation-ready workflows that simplify NGS library prep, while also demonstrating improved performance.

Michael Benway, NEB's Senior Automation Field Application Scientist, shared insights into the collaboration process. "By working closely with automation providers, we ensure that our NEBNext® reagents can be utilized in standardized workflows. This collaboration enables the adoption of these methods in laboratories around the globe, assuring our customers of their reliability," he expressed.

Benefits of Standardized Workflows

The emphasis on standardized workflows plays a crucial role in the success of NGS preparations across various organizations. Michael Mouradian, Vice President of Scientific Strategy at Hamilton Company, noted the importance of delivering robust, transferable methods. These methods significantly reduce implementation time and lessen the validation burden for labs looking to scale their NGS efforts.

Customer-Centric Solutions

NEB's focus on customer-centric solutions is evident in their collaborative approach, promoting not only automation but also ensuring that user needs are met effectively. Nicole Madamba, Senior Manager of Research Applications at Revvity, emphasized their commitment to developing solutions that can be endorsed globally, adapting to the requirements of customers across the globe.

Cutting-Edge Technology and Future Strategies

The partnership's emphasis on standardization not only optimizes hardware and software but also enhances the capability for these innovations to be readily adopted by laboratories. Paul Lomax, Genomics Leader at SPT Labtech, remarked on the software development methodologies applied to protocol design, stating that this revolutionary approach has significantly transformed NEB’s collaboration with automation firms.

NEB and its partners maintain a joint focus on solving customer challenges, ensuring scientists have access to high-quality results. Ewan Grant from Beckman Coulter Life Sciences points out that the intention has always been to align their goals with NEB's aspirations, which leads to overcoming substantial hurdles in automated NGS.

Upcoming Presentations at SLAS

At the upcoming Society for Laboratory Automation and Screening (SLAS) meeting, NEB will present a variety of impactful scientific posters showcasing these collaborations:

Poster: 1360-A
NEBNext® UltraShear FFPE DNA Library Prep Kit Automated on Revvity Sciclone™ G3 NGSx Workstation

Poster: 1211-B
Automation of NEBNext® UltraExpress® DNA Library Prep Kit on Revvity Sciclone™ G3 NGSx Workstation with Low Input cfDNA

Poster: 1206-B
Automation and Verification of the NEBNext® Enzymatic Methyl-seq v2 Library Preparation Workflow

Poster: 1207-C
Automation of NEBNext® Ultra II FS with Unique Molecular Indexes

Poster: 1209-E
Automation of NEBNext® Ultra™ II RNA Library Prep Kit

About New England Biolabs

New England Biolabs (NEB) stands at the forefront of molecular biology innovation. With over five decades of experience, NEB remains dedicated to producing products designed to advance research in the field. Their commitment extends beyond innovative products to include significant investments in research and development, as well as proactive efforts aimed at enhancing their workforce and environmental sustainability.

Operating a global network with headquarters in Ipswich, MA, NEB is a privately held company with extensive outreach, supported by numerous distribution partners. It is this commitment to quality and innovation that continues to position NEB as a leader in the industry.

Frequently Asked Questions

What is NEB’s mission in laboratory automation?

NEB aims to enhance next-generation sequencing workflows through strategic partnerships, ensuring efficient and reliable automation solutions for laboratories.

Who are NEB's major partners in automation?

NEB collaborates with Beckman Coulter, Eppendorf, Hamilton Company, Revvity, and SPT Labtech to improve laboratory automation for NGS library prep.

What impact do these partnerships have on researchers?

These collaborations lead to standardized, effective methodologies that simplify NGS workflows, saving time and improving outcomes for researchers.

Why are standardized workflows important?

Standardized workflows facilitate consistency, reliability, and quicker implementation of NGS processes in diverse laboratory settings.

How long has NEB been in operation?

New England Biolabs has been dedicated to molecular biology research for over 50 years, focusing on innovation and quality in their product offerings.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.